33 KB118 KB29 KB192920262007Gadžijev, EldarHorvat, MatjažIvanecz, ArpadPotrč, Stojanštevilka:47 straniletnik:76str. 237-243ISSN:1318-0347COBISSID:2632255URN:URN:NBN:SI:doc-4ZQAIBS4slSlovensko zdravniško društvoZdravniški vestnikColorectal Neoplasmsdankadebelo črevoHepatectomyHepatektomijajetrakirurško zdravljenjeKolorektalne novotvorbemortalityNeoplasm MetastasisNovotvorba, metastazaPooperativni zapletiPostoperative ComplicationspreživetjePreživetje, analizarak (medicina)Survival AnalysisUmrljivostzasevkiZdravljenje bolnikov z jetrnimi zasevki raka debelega črevesa in danke na Oddelku za abdominalno kirurgijo Splošne bolnišnice Maribor| The treatment of patients with colorectal liver metastases at the Deparment of abdominal surgery in the General hospital Maribor|Background. Liver resection, in collaboration with new diagnostic tools and chemotherapeutic agents, is the only potentially curative therapy for colorectal liver metastases (CRLM). Methods. In the period from January 1, 1996 to December 31, 2004, 94 patients with CRLM were treated in our department. Liver resection was possible for 84 patients. 110 procedures were performed in these patients. Results. At the end of the study (December 31, 2005), 22 patients were alive with no evidence of disease, 20 patients were alive with disease and 42 patients died of disease. The median follow-up for surviving patients was 33,8 months (from 13 to 123). The overall 5-year survival rate of the whole group of patients (R0 and R1 resections together) was 38 % with median survival 29.3 months. The overall 5-year survival of patients with R0 resection was 42 % with median survival of 32.3 months. The overall 5-year survival of patients with R1 resection was 29 % with median survival of 25.7 months. The postoperative complication rate was 23.8 % mortality was 2.3 %. Conclusions. Providing that decisions regarding the therapeutic approach are carried out in a multidisciplinary manner in specialized centers in collaboration with surgeons, oncologists and radiologists, we can offer a cure to some patients with CRLMIzhodišča. Resekcija jeter se je ob novih možnostih natančne diagnostike in uporabe kemoterapije do sedaj izkazala za edino potencialno kurativno zdravljenje jetrnih zasevkov raka debelega črevesa in danke (RDČD). Metode. V obdobju od 1. 1. 1996 do 31. 12. 2004 smo zdravili 94 bolnikov z jetrnimi zasevki RDČD. Pri 84 bolnikih je bila resekcija jeter možna. Pri teh bolnikih smo skupaj opravili 110 posegov. Rezultati. Ob zaključku analize (31. 12. 2005) je bilo 22 bolnikov živih brez recidiva bolezni, 20 bolnikov je bilo živih z recidivom, 42 bolnikov pa je umrlo zaradi napredovanja bolezni. Mediani čas sledenja preživelih bolnikov je bil 33,8 meseca (od 13 do 123). Skupno 5-letno preživetje je bilo 38 %, mediano preživetje pa 29,3 meseca za celotno skupino (R0 in R1 resekcije skupaj). Skupno 5-letno preživetje bolnikov z R0 je bilo 42 % z medianim preživetjem 32,3 meseca. Skupno 5-letno preživetje bolnikov z R1 resekcijo je bilo 29 % z medianim preživetjem 25,7 mesecev. Zapleti po operaciji so se pojavili pri 23,8 % bolnikih, pooperativna smrtnost je bila 2,3 %. Zaključki. Pod pogojem, da se odločitve o vrsti zdravljenja jetrnih zasevkov RDČD sprejemajo multidisciplinarno, v sodelovanju med kirurgi, onkologi in radiologi, in se zdravljenje izvaja v usposobljenih centrih, lahko nekaterim bolnikom z jetrnimi zasevki RDČD nudimo ozdravitevTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo